Close Menu

Cancer Research Technology

The new firm, created by Syncona and Cancer Research Technology, has raised $17.5 million to support development of individualized therapies targeted to tumor neoantigens.

Biomérieux has been awarded US Patent No. 8,106,172, "Nucleic acid sequences that can be used as primers and probes in the amplification and detection of SARS coronavirus."

In its companion diagnostics development program for an investigational PARP inhibitor oncologic, Pfizer is pursuing methylation-specific biomarkers rather than BRCA gene mutations to help personalize the drug.

MDxHealth will use its DNA methylation platform to identify and develop biomarkers that can predict patient response to a PARP inhibitor under development by Newcastle University, Cancer Research Technology, and Pfizer.

AstraZeneca and Cancer Research UK will contribute a combined £5.6 million ($8.9 million) to the Institute of Cancer Research to discover and develop cancer drugs that target molecular chaperones. AstraZeneca will have an exclusive worldwide license to compounds developed during the collaboration.

IBM security researchers warn of a phishing campaign targeted at organizations involved in the distribution of SARS-CoV-2 vaccines, the Verge reports.

The Illinois police have cut the number of DNA tests waiting to be run in about half, CBS Chicago reports.

A researcher accused of smuggling research materials out of the US has pleaded guilty to making false statements, according to the Associated Press.

In Science this week: gene expression signature linked to nonalcoholic fatty liver disease progression, and more.